Pediatric Liver Fat Quantification (LFQ) Phase 2 Pilot Study

該当なし完了 NCT04800094

対象疾患	Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis
相	該当なし
スポンサー	Philips Clinical & Medical Affairs Global
ステータス	完了
参加者数	30 名
介入（薬剤）	Investigational Liver Fat Quantification Software
開始日	2021年3月2日
完了日	2022年12月13日
結果公開日	2026年1月27日

概要

This clinical study will involve performing a series of medical imaging procedures of the abdomen using both ultrasound and MRI modalities in subjects at risk for or already diagnosed with Nonalcoholic Fatty Liver Disease (NAFLD). The primary objective of this clinical study is to evaluate the clinical feasibility of an investigational ultrasound technique for quantifying liver fat by comparing specific ultrasound-derived biomarkers with the liver fat percentage obtained from MRI Proton Density Fat Fraction (MRI-PDFF) measurements. All subjects enrolled in this study will undergo one investigational abdominal ultrasound examination using the Philips EPIQ Ultrasound System and one MRI PDFF examination according to the clinical standard of care.

Correlation of the Liver Fat Percentage Reported From MRI-PDFF With Measurements of Hepatorenal Index (HRI) Ultrasound Biomarker for Liver Fat.

Intra-procedural (1 day) · Hepatorenal Index

Hepatorenal Index: Investigational Ultrasound Imaging for Liver Fat Quantification	1.7 ± 0.7 Hepatorenal Index

Pearson correlation coefficient	0.4459

Correlation of the Liver Fat Percentage Reported From MRI-PDFF With Measurements of Acoustic Attenuation (dB/cm/MHZ) Ultrasound Biomarker for Liver Fat.

Intra-procedural (1 day) · dB/CM/MHz

Acoustic Attenuation: Investigational Ultrasound Imaging for Liver Fat Quantification	0.6 ± 0.1 dB/CM/MHz

Pearson correlation coefficient	0.1742

Correlation of the Liver Fat Percentage Reported From MRI-PDFF With Measurements of Tissue Stiffness (kPa) Ultrasound Biomarkers for Liver Fat.

Intra-procedural (1 day) · kPa

Tissue Stiffness: Investigational Ultrasound Imaging for Liver Fat Quantification	6.6 ± 1.6 kPa

Pearson correlation coefficient	0.0810

BENITIONS で見る ClinicalTrials.gov の原文を見る

同じ疾患の他の治験

A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatoh — Akero Therapeutics, Inc
Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Va — Galectin Therapeutics Inc.
Iron Reduction for the Treatment of Diabetes and Nonalcoholic Fatty Liver Disease — Wake Forest University Health Sciences
Effect of Obesity on Proton Pump Inhibitors — Children's Mercy Hospital Kansas City
Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatoti — Merck Sharp & Dohme LLC
Phase 2a Study of HPG1860 in Subjects With NASH — Hepagene (Shanghai) Co., Ltd.

すべての治験

このページは ClinicalTrials.gov の公開データをまとめたものです。医学的助言ではなく、投資助言でもありません。必ず専門医にご相談ください。

English 한국어 日本語中文 Русский